A complex between 6-iodolactone and the peroxisome proliferator-activated receptor type gamma may mediate the antineoplasic effect of iodine in mammary cancer

Prostaglandins and Other Lipid Mediators

Volumn 89, Issue 1-2, 2009, Pages 34-42

  Nunez Anita R E ^a   Arroyo Helguera, O ^a   Cajero Juarez M ^b   Lopez Bojorquez L ^a   Aceves, C ^a  

^a INSTITUTO DE NEUROBIOLOGÍA   (Mexico)

^b UNIVERSIDAD MICHOACANA DE SAN NICOLÁS DE HIDALGO   (Mexico)

Author keywords

6 Iodolactone; Arachidonic acid; EMSA; Iodine; Mammary cancer; MCF 7; PPAR; Transfection

Indexed keywords

6 IODO 5 HYDROXY EICOSATRIENOIC ACID; 6 IODOLACTONE; ARACHIDONIC ACID DERIVATIVE; BETA ACTIN; CASPASE; IODINE 125; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; BREAST CANCER; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; ISOTOPE LABELING; LIPID STORAGE; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; THIN LAYER CHROMATOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; ARACHIDONIC ACID; ARACHIDONIC ACIDS; BREAST NEOPLASMS; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IODINE; IODINE RADIOISOTOPES; PPAR ALPHA; PPAR GAMMA; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; RESPONSE ELEMENTS; RETINOID X RECEPTORS; STAINING AND LABELING;

EID: 65649112487     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2009.04.001     Document Type: Article

References (51)

1. Funahashi H., Imai T., Tanaka Y., et al. Suppressive effect of iodine on DMBA-induced breast tumor growth in the rat. J Surg Oncol 61 (1996) 209-213
2. 2 prevents cancer promotion. Mol Cell Endocrinol 236 (2005) 49-57
3. Arroyo-Helguera O., Delgado G., Anguiano B., and Aceves C. Uptake and antiproliferative effect of molecular iodine in the MCF-7 breast cancer cell line. Endocr Relat Cancer 13 (2006) 1147-1158
4. Shrivastaba A., Tiwari M., Sinha R.A., et al. Molecular iodine induces caspase-independent apoptosis in human breast carcinoma cells involving mitochondria-mediated pathway. J Biol Chem 281 (2006) 19762-19771
5. Arroyo-Helguera O., Rojas E., Delgado G., and Aceves C. Signaling pathways involved in the antiproliferative effect of molecular iodine in normal and tumoral breast cells: evidence that 6-iodolactone mediates apoptotic effects. Endocr Relat Cancer 15 (2008) 1003-1011
6. Vitale M., Di Matola T., D'Ascoli F., et al. Iodide excess induces apoptosis in thyroid cells through a p53-independent mechanism involving oxidative stress. Endocrinology 141 (2000) 598-605
7. Zhang L., Sharma S., Zhu L.X., et al. Nonradioactive iodide effectively induces apoptosis in genetically modified lung cancer cells. Cancer Res 63 (2003) 5065-5072
8. Pisarev M.A., and Gartner R. Autorregulatory actions of iodine. In: Braverman L.E., and Utiger R.D. (Eds). Werner and Ingbar's the thyroid. The fundamental and clinical text. 8th ed. (2000), Lippincott Williams and Wilkins, NY 85-90
9. Pisarev M.A., Krawiec L., Juvenal G.J., et al. Studies on the goiter inhibiting action of iodolactones. Eur J Pharmacol 258 (1994) 33-37
10. Langer R., Burzler C., Bechtner G., and Gârtner R. Influence of iodide and iodolactones on thyroid apoptosis. Exp Clin Endocrinol Diabetes 111 (2003) 325-329
11. Krey G., Braissant O., L'Horset O., et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 11 (1997) 779-790
12. Forman B.M., Chen J., and Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci USA 94 (1997) 4312-4317
13. Berger J., and Moller D.E. The mechanisms of action of PPAR. Annu Rev Med 53 (2002) 409-435
14. Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20 (1999) 649-688
15. Suchanek K.M., May F.J., Robinson J.A., et al. Peroxisome proliferators-activated receptor a in the human breast cancer cell lines MCF-7 and MDA MB-231. Mol Carcinog 34 (2002) 165-171
16. Pighetti G.M., Novosad W., Nicholson C., et al. Therapeutic treatment of DMBA-induced mammary tumors with PPAR ligands. Anticancer Res 21 (2001) 825-830
17. Miller R.T., Glover S.E., Stewart W.S., Corton J.C., Popp J.A., and Cattley R.C. Effect on the expression of c-met, c-myc and PPAR-α in liver and liver tumors from rats chronically exposed to the hepatocarcinogenic peroxisome proliferator WY-14, 643. Carcinogenesis 17 (1996) 1337-1341
18. Peters J.M., Cattley R.C., and Gonzales F.J. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14, 643. Carcinogenesis 18 (1997) 2029-2033
19. Roberts R.A., James N.H., Woodyatt N.J., Macdonald N., and Tugwood J.D. Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPAR alpha). Carcinogenesis 19 (1998) 43-48
20. Stephen R.L., Gustafsson M.C., Jarvis M., et al. Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res 64 (2004) 3162-3170
21. Yin Y., Russell R.G., Dettin L.E., et al. Peroxisome proliferator-activated receptor δ and γ agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res 65 (2005) 3950-3957
22. Mueller E., Sarraf P., Tontonoz P., et al. Terminal differentiation of human breast cancer through PPARγ. Mol Cell 1 (1998) 465-470
23. Elstner E., Müller C., Koshizuka K., et al. Ligand for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibits growth and induces apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95 (1998) 8806-8811
24. Yin F., Wakino S., Liu Z., et al. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. BBRC 286 (2001) 916-922
25. Lapillonne H., Konopleva M., Tsao T., et al. Activation of peroxisome proliferator-activated receptor γ by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res 63 (2003) 5926-5939
26. Dugrillon A., Uedelhoven W.M., Pisarev M.A., Betchner G., and Gartner R. Identification of delta-iodolactone in iodide treated human goiter and its inhibitory effect on proliferation of human thyroid follicles. Horm Metab Res 26 (1994) 465-469
27. Andrews N.C., and Faller D.V. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucl Acids Res 19 (1991) 2499-2503
28. Molecular station http://www.celldeath.de/apometh/emsa.html.
29. Girnun G.D., Domann F.E., Moore S.A., and Robbins M.E.C. Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol Endocrinol 16 (2002) 2793-2801
30. Sambrook J., Fritsch E.F., and Manniatis T. Molecular cloning in: a laboratory manual. 2nd ed. (1989), Cold Spring Harbor Laboratory p. 3-16.32
31. Umesono K., Murakami K.K., Thompson C.C., and Evans R.M. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell 65 (1991) 1255-1266
32. Anguiano B., García-Solís P., Delgado G., and Aceves C. Uptake and gene expression with antitumoral doses of iodine in thyroid and mammary gland: evidence that chronic administration has no harmful effects. Thyroid 17 (2007) 851-859
33. Laemmli U.K. Cleavage of structural proteins during the assembly of head of bacteriophage T4. Nature 227 (1970) 680-685
34. Fajas L., Auboeuf D., Raspé E., et al. The organization, promoter analysis, and expression of the human PPARγ gene. J Biol Chem 272 (1997) 18779-18789
35. Heinemeyer T., Wingender E., Reuter I., et al. Databases on transcriptional regulation: TRANSFAC, TRRD, and COMPEL. Nucl Acids Res 26 (1998) 364-370
36. http://www.cbrc.jp/research/db/TFSEARCH.html.
37. Greene, and Kehinde O. Sublines of mouse 3T3 cells that accumulate lipid. Cell 1 (1974) 113-116
38. Michalik L., Desvergne B., and Whali W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev 4 (2004) 61-70
39. Samid D., Wells M., Greene M.E., Shen W., Palmer C.N., and Thibault A. Peroxisome proliferator-activated receptor γ as a novel target in cancer therapy: binding and activation by aromatic fatty acid with clinical antitumoral activity. Clin Cancer Res 6 (2000) 933-941
40. Pisarev M.A., and Kleiman de Pisarev D.L. Biochemistry of thyroid regulation under normal and abnormal conditions. J Endocrinol Invest 3 (1980) 317-328
41. Razanamahefa L., Prouff S., and Bardon S. Stimulatory effect of arachidonic acid on T-47D human breast cancer cell growth is associated with enhancement of cyclin D1 mRNA expression. Nutr Cancer 38 (2000) 274-280
42. Bennett A., Charlier E.M., McDonald A.M., Simpson J.S., Stamford I.F., and Zebro T. Prostaglandins and breast cancer. Lancet 24 (1977) 219-225
43. Rolland P.H., Martin P.M., Jacquemier J., Rolland A.M., and Toga M. Prostaglandins in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Nat Cancer Inst 64 (1980) 1061-1070
44. Tan W.C., Privett O.S., and Goldyne M.E. Studies of prostaglandins in rat mammary tumors induced by 7,12-dymethyl-benzantracene. Cancer Res 34 (1974) 3229-3231
45. Aceves C, García-Solís P, Arroyo-Helguera O, et al. Antineoplastic effect of iodine in mammary cancer. Participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR). Molecular Cancer, 2009, in press.
46. Mandard S., Müller M., and Kersten S. Peroxisome proliferator-activated receptor α target genes. Cell Mol Life Sci 61 (2004) 393-416
47. Pineda-Torra I., Jamshidi Y., Flavell D.M., Fruchart J.C., and Staels B. Characterization of the human PPARα promoter: identification of functional nuclear receptor response element. Mol Endocrinol 16 (2002) 1013-1028
48. Fregman H., Andersson L., and Nilsson M. The developing mouse thyroid: embryonic vessel contacts and parenchymal growth pattern during specification, budding, migration, and lobulation. Dev Dyn 235 (2006) 444-455
49. Dentice M., Luongo C., Elefante A., et al. Transcription factor Nkx-2.5 induces sodium/iodide symporter gene expression and participates in retinoic acid- and lactation-induced transcription in mammary cells. Mol Cell Biol 24 (2004) 7863-7878
50. 2 to activate PPARβ. FEBS J 273 (2006) 170-179
51. Terashita Y., Sasaki H., Haruni N., et al. Decreased peroxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer. Jpn J Clin Oncol 32 (2002) 238-243